Tropomyosin-Related Kinase (TRK) Inhibitors
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 62/040,750, filed Aug 22, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,067,914 | Tropomyosin-Related Kinase (TRK) Inhibitors In force · High confidence | Genzyme Corporation | In force | High confidence | ||
| US 9,174,986 | Tropomyosin-Related Kinase (TRK) Inhibitors In force · High confidence | Genzyme Corporation | In force | High confidence | ||
| US 9,611,265 | Tropomyosin-Related Kinase (TRK) Inhibitors In force · High confidence | Genzyme Corporation | In force | High confidence | ||
| US 10,166,239 | Tropomyosin-Related Kinase (TRK) Inhibitors In force · High confidence | Genzyme Corporation | In force | High confidence | ||
| US 11,406,644 | Tropomyosin-Related Kinase (TRK) Inhibitors In force · High confidence | Genzyme Corporation | In force | High confidence | ||
| US 11,878,024 | Tropomyosin-Related Kinase (trk) Inhibitors In force · High confidence | Genzyme Corporation | In force | High confidence | ||
| US 12,318,392 | Tropomyosin-Related Kinase (trk) Inhibitors In force · High confidence | Genzyme Corporation | In force | High confidence | ||
| Application 16/194,696 | Tropomyosin-Related Kinase (TRK) Inhibitors Abandoned Abandoned Oct 9, 2020 | Genzyme Corporation | Abandoned | Abandoned Oct 9, 2020 | ||
| Application 19/223,215 | Tropomyosin-Related Kinase (TRK) Inhibitors Pending Not granted | Genzyme Corporation | Pending | Not granted |
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
7 of these are in force and held by Genzyme Corporation.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.